REGISTERED NUMBER: |
Financial Statements for the Year Ended 31st May 2024 |
for |
Delta Pharmaceutics Limited |
REGISTERED NUMBER: |
Financial Statements for the Year Ended 31st May 2024 |
for |
Delta Pharmaceutics Limited |
Delta Pharmaceutics Limited (Registered number: 08059569) |
Contents of the Financial Statements |
for the year ended 31st May 2024 |
Page |
Company Information | 1 |
Statement of Financial Position | 2 |
Notes to the Financial Statements | 4 |
Delta Pharmaceutics Limited |
Company Information |
for the year ended 31st May 2024 |
DIRECTOR: |
REGISTERED OFFICE: |
REGISTERED NUMBER: |
ACCOUNTANTS: |
Chartered Accountants |
1-3 Manor Road |
Chatham |
Kent |
ME4 6AE |
Delta Pharmaceutics Limited (Registered number: 08059569) |
Statement of Financial Position |
31st May 2024 |
2024 | 2023 |
Notes | £ | £ | £ | £ |
FIXED ASSETS |
Tangible assets | 4 |
CURRENT ASSETS |
Debtors | 5 |
Cash at bank |
CREDITORS |
Amounts falling due within one year | 6 |
NET CURRENT ASSETS |
TOTAL ASSETS LESS CURRENT LIABILITIES |
PROVISIONS FOR LIABILITIES |
NET ASSETS |
CAPITAL AND RESERVES |
Called up share capital | 7 |
Retained earnings | 8 |
SHAREHOLDERS' FUNDS |
The director acknowledges his responsibilities for: |
(a) | ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and |
(b) | preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company. |
Delta Pharmaceutics Limited (Registered number: 08059569) |
Statement of Financial Position - continued |
31st May 2024 |
In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered. |
The financial statements were approved by the director and authorised for issue on |
Delta Pharmaceutics Limited (Registered number: 08059569) |
Notes to the Financial Statements |
for the year ended 31st May 2024 |
1. | STATUTORY INFORMATION |
Delta Pharmaceutics Limited is a |
2. | ACCOUNTING POLICIES |
Basis of preparing the financial statements |
Turnover |
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. |
Tangible fixed assets |
Plant and machinery | - |
Research grants |
Research grants in relation to revenue are recognised in income on a systematic basis over the periods in which the entity recognises the related costs for which the grant is intended to compensate. |
Taxation |
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. |
Current or deferred taxation assets and liabilities are not discounted. |
Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the statement of financial position date. |
Deferred tax |
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the statement of financial position date. |
Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference. |
Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. |
3. | EMPLOYEES AND DIRECTORS |
The average number of employees during the year was |
Delta Pharmaceutics Limited (Registered number: 08059569) |
Notes to the Financial Statements - continued |
for the year ended 31st May 2024 |
4. | TANGIBLE FIXED ASSETS |
Plant and |
machinery |
etc |
£ |
COST |
At 1st June 2023 |
Additions |
At 31st May 2024 |
DEPRECIATION |
At 1st June 2023 |
Charge for year |
At 31st May 2024 |
NET BOOK VALUE |
At 31st May 2024 |
At 31st May 2023 |
5. | DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |
2024 | 2023 |
£ | £ |
Trade debtors |
Other debtors and prepayments |
6. | CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |
2024 | 2023 |
£ | £ |
Corporation tax |
Social security and other taxes |
Other creditors and accruals |
Delta Pharmaceutics Limited (Registered number: 08059569) |
Notes to the Financial Statements - continued |
for the year ended 31st May 2024 |
7. | CALLED UP SHARE CAPITAL |
Allotted, issued and fully paid: |
Nominal | 2024 | 2023 |
Number: | Class: | value: | £ | £ |
20,070 | Ordinary | £1 | 20,070 | 70 |
10,035 | A Ordinary | £1 | 10,035 | 35 |
65 | B Ordinary | £1 | 65 | 65 |
10 | C Ordinary | £1 | 10 | 10 |
10 | D Ordinary | £1 | 10 | 10 |
10 | E Ordinary | £1 | 10 | 10 |
30,200 | 200 |
During the year the company issued 20,000 Ordinary shares and 10,000 A Ordinary shares at par value. |
8. | RESERVES |
Retained |
earnings |
£ |
At 1st June 2023 |
Profit for the year |
At 31st May 2024 |
9. | ULTIMATE CONTROLLING PARTY |
The controlling party is D Douroumis. |